Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
Clinical trial NCT03030378 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03030378
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-30
- Primary completion
- 2026-12-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.